BACKGROUND: Data on long-term intra-individual variability in high-sensitivity C-reactive protein (hsCRP) are needed to determine whether one measurement adequately reflects usual levels in prospective studies of on the etiology of cancer and other chronic diseases; when not reflective, the ability to statistically detect modest to moderate associations is reduced. The authors estimated the size of this source of variability and consequent attenuation of the relative risk (RR). METHODS: High-sensitivity C-reactive protein (hsCRP) concentration was measured using a high-sensitivity immunoturbidometric assay in sera collected at years 2, 4, and 6 from 50 men in the placebo arm of the Prostate Cancer Prevention Trial (PCPT). After natural logarithm-transformation of hsCRP, analysis of variance was used to estimate the within- and between-individual variances from which the intra-class correlation coefficient (ICC) was calculated. RESULTS: The observed RR due to an ICC < 1 was calculated by e((ln true RR*ICC)) for a range of true RRs. The 4-year ICC was 0.66. Measuring hsCRP once and assuming no other error, if the true RRs were 1.50, 2.00, and 3.00 when comparing high with low concentration, then the observed RRs would be 1.31, 1.58, and 2.06, respectively. CONCLUSION: Investigators planning to measure hsCRP only once should design adequately sized studies to preserve inferences for hypothesized modest to moderate RRs.
BACKGROUND: Data on long-term intra-individual variability in high-sensitivity C-reactive protein (hsCRP) are needed to determine whether one measurement adequately reflects usual levels in prospective studies of on the etiology of cancer and other chronic diseases; when not reflective, the ability to statistically detect modest to moderate associations is reduced. The authors estimated the size of this source of variability and consequent attenuation of the relative risk (RR). METHODS: High-sensitivity C-reactive protein (hsCRP) concentration was measured using a high-sensitivity immunoturbidometric assay in sera collected at years 2, 4, and 6 from 50 men in the placebo arm of the Prostate Cancer Prevention Trial (PCPT). After natural logarithm-transformation of hsCRP, analysis of variance was used to estimate the within- and between-individual variances from which the intra-class correlation coefficient (ICC) was calculated. RESULTS: The observed RR due to an ICC < 1 was calculated by e((ln true RR*ICC)) for a range of true RRs. The 4-year ICC was 0.66. Measuring hsCRP once and assuming no other error, if the true RRs were 1.50, 2.00, and 3.00 when comparing high with low concentration, then the observed RRs would be 1.31, 1.58, and 2.06, respectively. CONCLUSION: Investigators planning to measure hsCRP only once should design adequately sized studies to preserve inferences for hypothesized modest to moderate RRs.
Authors: Wolfgang Koenig; Malte Sund; Margit Fröhlich; Hannelore Löwel; Winston L Hutchinson; Mark B Pepys Journal: Am J Epidemiol Date: 2003-08-15 Impact factor: 4.897
Authors: P A Sakkinen; E M Macy; P W Callas; E S Cornell; T E Hayes; L H Kuller; R P Tracy Journal: Am J Epidemiol Date: 1999-02-01 Impact factor: 4.897
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2003-06-24 Impact factor: 91.245
Authors: M P de Maat; A C de Bart; B C Hennis; P Meijer; A C Havelaar; P G Mulder; C Kluft Journal: Arterioscler Thromb Vasc Biol Date: 1996-09 Impact factor: 8.311
Authors: Ying Wang; Brian D Carter; Susan M Gapstur; Marjorie L McCullough; Mia M Gaudet; Victoria L Stevens Journal: Metabolomics Date: 2018-09-25 Impact factor: 4.290
Authors: Sarah C Markt; Jennifer R Rider; Kathryn L Penney; Fredrick R Schumacher; Mara M Epstein; Katja Fall; Howard D Sesso; Meir J Stampfer; Lorelei A Mucci Journal: Prostate Date: 2014-05-20 Impact factor: 4.104
Authors: Anil K Chaturvedi; Troy J Kemp; Ruth M Pfeiffer; Angelique Biancotto; Marcus Williams; Stella Munuo; Mark P Purdue; Ann W Hsing; Ligia Pinto; J Philip McCoy; Allan Hildesheim Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-06-29 Impact factor: 4.254
Authors: Heather S McKay; Joseph B Margolick; Otoniel Martínez-Maza; Joseph Lopez; John Phair; Giovanna Rappocciolo; Thomas N Denny; Larry I Magpantay; Lisa P Jacobson; Jay H Bream Journal: Cytokine Date: 2016-12-09 Impact factor: 3.861
Authors: Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-24 Impact factor: 4.254
Authors: Anna E Prizment; Aaron R Folsom; Jill Dreyfus; Kristin E Anderson; Kala Visvanathan; Corinne E Joshu; Elizabeth A Platz; James S Pankow Journal: Cancer Causes Control Date: 2013-09-14 Impact factor: 2.506
Authors: Wenjie Ma; Manol Jovani; Long H Nguyen; Fred K Tabung; Mingyang Song; Po-Hong Liu; Yin Cao; Idy Tam; Kana Wu; Edward L Giovannucci; Lisa L Strate; Andrew T Chan Journal: Clin Gastroenterol Hepatol Date: 2019-11-08 Impact factor: 11.382